19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Kids Raised by Grandparents More Likely to Pile on Pounds: StudyKeep Your Kids Safe, Warm in Wintertime FunHow to Dispel Your Child's Fears About the New CoronavirusDiabetes Among U.S. Young, Especially Asians, Continues to ClimbMom-to-Be's Cosmetics Chemicals Could Lead to Heavier BabyMeds May Not Prevent Migraines in KidsAHA News: For Kids With Heart Defects, the Hospital Near Mom May Matter1 in 4 Gets Unneeded Antibiotics at Children's HospitalsVitamin D in Pregnancy Doesn't Curb Kids' AsthmaFirst Drug Approved for Treatment of Peanut Allergy in ChildrenWhat's the Best Treatment for a Child's Broken Bone?Are Antibiotics a Recipe for Obesity in Childhood?This Year's Flu Season Taking Deadly Aim at KidsWhy Are Fewer U.S. Kids Going to Pediatricians?Severe Deprivation in Childhood Has Lasting Impact on Brain SizeHealth Tip: What Your Child Can do About BullyingWildfires Send Kids to ERs for Breathing ProblemsTV Can Be a Good Influence on Kids' Eating HabitsWould Tighter Swimming Rules at Public Beaches, Lakes and Rivers Save Lives?U.S. Doctors Often Test, Treat Kids UnnecessarilyHealth Tip: Safety Steps if Your Child is Home AloneHealth Tip: Help Your Child Safely Lose WeightAmericans Need to Tackle Youth Obesity: U.S. Task ForceGenes, Family Are Key Predictors of School SuccessKids' 'Microbiome' May Play Key Role in AsthmaA Puppy in Santa's Sack? Probably Not, Say ParentsMore Kids, Teens Landing in ERs After Opioid OverdosesGetting Active Helps Kids' Hearts, Even in the ObeseWhen Does Your Child's Flu Merit an ER Visit?Health Tip: Managing Hearing Loss in ChildrenHealth Tip: Is My Child Too Sick to Go to School?Differences Found in Brains of Kids Born to Depressed ParentsSecondhand Smoke Starts Kids on Path to Heart Disease: StudyHealth Tip: Choosing a PediatricianMany Kids Traveling Overseas Aren't Vaccinated Against MeaslesCould Obesity Alter a Child's Brain Structure?Dramatic Rise in Eye Injuries From BB and Paintball GunsTwo-Thirds of Child Abuse Survivors Do Well as AdultsAHA News: Serious Heart Defects Increase Heart Failure Risk in Early AdulthoodMore U.S. Kids Are Shunning Sweetened DrinksAs Disease Outbreaks Tied to 'Anti-Vaxxers' Rise, States Take Action'Don't Give Up:' Parents' Intuition Spots a Rare Illness Before Doctors DoFDA Approves First Contact Lens That Slows Myopia ProgressionStereotypes About Girls and Math Don't Add Up, Scans ShowStudies Confirm HPV Shot Is SafeThese Sports Are Most Likely to Send Young Americans to the ERNature Nurtures KidsClimate Change Will Hurt Kids Most, Report WarnsTough Childhoods Can Leave a Lifetime of Harm, Experts SayMany U.S. Parents Can't Find a Psychiatrist to Help Their Child
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

First Drug Approved for Treatment of Peanut Allergy in Children


HealthDay News
Updated: Feb 3rd 2020

new article illustration

MONDAY, Feb. 3, 2020 (HealthDay News) -- The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to alleviate allergic reactions to accidental peanut exposure, the agency announced late Friday.

Palforzia, a powder manufactured from peanuts, is indicated for initiation in individuals aged 4 to 17 years old with a confirmed peanut allergy. Treatment may be continued in individuals aged 4 years and older. "When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release.

The FDA notes that Palforzia cannot be used for emergency treatment of allergic reactions. Treatment involves three phases, including initial dose escalation, given on a single day; up-dosing, which involves 11 increasing dose levels over several months; and maintenance. The initial dose escalation and the first dose of each up-dosing level are administered under the supervision of a health care professional. Once patients have completed all up-dosing levels, they can begin the maintenance phase. Palforzia is packaged in pull-apart color-coded capsules for the dose escalation and up-dosing levels and is packaged in a sachet for maintenance treatment. The powder from the capsules or sachet is to be mixed with a small amount of food such as applesauce, yogurt, or pudding for the patient to consume.

Approval was based on data from a randomized, double-blind, placebo-controlled study in about 500 peanut-allergic individuals. In an oral challenge after six months of maintenance treatment, 67.2 percent of individuals who received Palforzia tolerated a 600-mg dose of peanut protein with no more than mild allergic symptoms versus 4 percent of those who received placebo. In two double-blind, placebo-controlled studies of about 700 peanut-allergic individuals, the most commonly reported side effects with Palforzia included abdominal pain, vomiting, nausea, tingling in the mouth, itching in the mouth and ears, cough, runny nose, throat irritation and tightness, hives, wheezing, and shortness of breath and anaphylaxis.

Approval was granted to Aimmune Therapeutics.

More Information